Landiolol in supraventricular tachycardia: an updated review of clinical applications

Supraventricular tachycardia (SVT) is a prevalent cardiac arrhythmia requiring rapid and effective intervention. Landiolol, a highly selective, ultra-short acting, beta-1 adrenergic receptor blocker, has recently received FDA approval for short-term ventricular rate control in adults with SVT, including atrial fibrillation and atrial flutter. Its rapid onset and hemodynamic stability make it a valuable addition to acute cardiac care. Data from clinical trials, systematic reviews, and real-world studies were analyzed to evaluate landiolol’s role in SVT management. It effectively controls the ventricular rate in SVT. The drug exhibited a favourable safety profile and is better suited for rate control rather than arrhythmia termination when compared to adenosine. Its utility in managing perioperative atrial fibrillation, critically ill patients, and those with respiratory conditions makes it a valuable therapeutic option. Future research should explore its role in Indian demographics to optimize its clinical use.